FDA Approves Pfizer's Talzenna Plus Xtandi for HRR-Mutated Hormone-Sensitive Prostate Cancer
The U.S. Food and Drug Administration has cleared Pfizer's Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with metastatic prostate cancer that still responds to hormone therapy and carries a homologous recombination repair (HRR) gene mutation, the company said on Oct. 26, 2026, in New York. The decision moves the oral PARP inhibitor regimen into an earlier stage of the disease, known as metastatic androgen pathway modulation-naive or -sensitive prostate cancer, and covers both BRCA and non-BRCA HRR alterations identified with an FDA-authorized test.
Key developments
- The FDA expanded the combination's label to adults with HRR gene-mutated metastatic prostate cancer that has not been treated with, or remains sensitive to, androgen pathway drugs. The review ran under Priority Review and Project Orbis.
- Approval rests on the Phase 3 TALAPRO-3 trial, which randomized 599 patients to talazoparib 0.5 mg daily or placebo, each with enzalutamide 160 mg daily.
- Talazoparib plus enzalutamide cut the risk of radiographic progression or death by 52% (hazard ratio 0.48; 95% CI, 0.36-0.65; p<0.0001), with Pfizer estimating that 77% of patients were progression-free at three years.
- Grade 3 or higher anemia occurred in 51% of patients on the combination versus 3% in the control arm, and 5% stopped talazoparib because of anemia. Overall survival data remain under evaluation.
- A parallel application is under review at the European Medicines Agency. The combination is already approved in more than 60 countries for other settings.
Disease and treatment background
Prostate cancer that has spread but still responds to hormone suppression is usually treated with androgen deprivation therapy plus a newer androgen pathway drug such as enzalutamide. Many patients eventually progress to castration-resistant disease, where options narrow and outcomes worsen. Pfizer says about 25% of men in the hormone-sensitive metastatic setting carry HRR gene mutations, a group that has tended to progress faster on standard hormone therapy.
HRR genes, including BRCA1 and BRCA2, help cells repair DNA damage. Tumors with defects in these genes are more vulnerable to PARP inhibitors, which block a second repair route. Talazoparib, sold as Talzenna, first won U.S. approval as a single agent in germline BRCA-mutated, HER2-negative breast cancer. The FDA then cleared its pairing with enzalutamide in June 2023 for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 study. Xtandi is jointly developed and commercialized in the United States by Pfizer and Astellas.
TALAPRO-3 was randomized, double-blind and placebo-controlled, with investigator-assessed radiographic progression-free survival as its primary endpoint. Results were presented at the 2026 ASCO Annual Meeting and published in The New England Journal of Medicine. Pfizer reported consistent benefit in both BRCA and non-BRCA subgroups. The most common adverse events were anemia, fatigue, decreased neutrophil count and asthenia, and the company said it saw no new safety signals. The label carries warnings for myelodysplastic syndrome and acute myeloid leukemia, myelosuppression and embryo-fetal toxicity.
Industry implications
The decision extends a targeted therapy into a stage of prostate cancer where patients may stay on treatment for years. Pfizer's chief U.S. commercial officer, Aamir Malik, framed the approval as building on the regimen's existing standard-of-care role in later-stage disease. For prescribers, the practical change is that the combination becomes available before resistance develops, rather than after hormone therapy fails.
The approval also raises the stakes for genetic testing. Neeraj Agarwal, the trial's global lead investigator, stressed the importance of biomarker testing at the time of diagnosis. Because the label requires an HRR mutation confirmed by an FDA-authorized test, uptake will depend heavily on how quickly urology and oncology practices make tissue or liquid biopsy profiling routine for newly diagnosed metastatic patients. That creates a direct link between the drug's commercial reach and the capacity of diagnostics providers and reimbursement systems.
The safety profile will shape real-world use. Anemia severe enough to require monitoring, dose changes or transfusion affected about half of treated patients in the trial, so clinics will need monthly blood counts and supportive care plans for patients who may stay on therapy for long periods.
Competitive and supply chain implications
Pfizer is not alone in pushing PARP-based regimens earlier. In December 2025, the FDA approved Johnson & Johnson's Akeega, a fixed-dose combination of niraparib and abiraterone acetate taken with prednisone, for BRCA2-mutated metastatic castration-sensitive prostate cancer. Pfizer's label is broader on the genetic side, covering BRCA and non-BRCA HRR alterations, while J&J's applies to the BRCA2 subgroup. AstraZeneca's Lynparza remains approved with abiraterone in later-stage BRCA-mutated disease.
The result is a market where oncologists will choose among androgen pathway backbones, PARP partners and specific mutation profiles. Differences in label breadth, toxicity, pill burden and steroid use are likely to drive those choices more than headline efficacy alone, since cross-trial comparisons are unreliable.
On the supply side, the expansion adds demand for both talazoparib and enzalutamide, two small-molecule oral drugs, along with companion diagnostic testing. Because the regimen is given until progression or unacceptable toxicity, longer treatment duration in an earlier setting could increase per-patient volume for both products.
Regional implications
The U.S. decision comes first, but Project Orbis, which lets partner regulators review oncology applications in parallel, may speed decisions in participating countries. In Europe, the EMA is reviewing the same indication. The European Commission had already approved the combination in January 2024 for castration-resistant disease in patients for whom chemotherapy is not clinically indicated.
Access outside the United States will depend on local reimbursement and the availability of HRR testing, which varies widely between health systems. Markets with established genomic testing networks are likely to adopt the earlier indication fastest once regulators act.
Credence Research analysis
The approval reflects a wider shift in oncology toward moving targeted drugs into earlier, longer treatment settings once a biomarker-defined group shows a clear progression benefit. Pfizer's case is strengthened by the size of the hazard ratio and the consistency across BRCA and non-BRCA mutations, which gives it a broader eligible population than BRCA-only competitors. The key open question is overall survival. Pfizer itself lists the secondary survival endpoint as an uncertainty, and the control arm's 45.8-month median progression-free survival, as reported in FDA labeling summaries, shows that enzalutamide alone already controls disease for a long time.
That combination of strong progression data and an immature survival picture means payers and guideline committees will weigh the anemia burden carefully. Testing rates may prove to be the bigger constraint. A regimen gated by a genetic test reaches only as many patients as are tested, so Pfizer's commercial effort is likely to lean on diagnostic awareness as much as on the drug itself.
What comes next
- Overall survival results from TALAPRO-3, the trial's key secondary endpoint.
- A decision from the European Medicines Agency on the hormone-sensitive indication.
- Possible decisions from Project Orbis partner regulators.
- Updates to clinical practice guidelines on HRR testing and PARP combinations in metastatic hormone-sensitive disease.
- Uptake data as testing at diagnosis expands across U.S. practices.
Sources
- Pfizer: TALZENNA plus XTANDI FDA-approved for an earlier metastatic prostate cancer treatment setting
- FDA: Talazoparib with enzalutamide approval for HRR gene-mutated mCRPC (2023)
- Johnson & Johnson: FDA approves Akeega for BRCA2-mutated mCSPC
Image: Pfizer buildings in Groton, Connecticut, by Pi.1415926535 via Wikimedia Commons, CC BY-SA 4.0. Cropped and edited by Credence Research.
About the Author
Senior News Editor at Credence Research Inc